Abstract Details

Title Does the Location Matter? Characterization of the Anatomic Locations, Molecular Profiles, and Clinical Features of Gliomas

Topic Neuro-oncology

Presentation(s) P1 - Poster Session 1 (12:00 PM-1:00 PM)

Poster/Presentation
Number 13-014

Objective To analyze the effect of neuro-anatomical location on tumor molecular profiles and patients' clinical courses.

Background Locations of gliomas may influence clinical presentations, molecular profiles, treatment options, and prognoses. Using the Mayo Clinic Arizona Cancer Center registry, we analyzed the frequency at which gliomas were identified in different regions of the brain. We evaluated molecular profiles, clinical courses and survival by anatomic location.

Design/Methods Registry was queried to include patients with glioma over a 10-year period. Statistical analyses were used to compare demographic, genetic, and clinical characteristics among patients with gliomas in different locations.

Results 182 gliomas were identified. Of tumors confined to a single lobe, there were 51 frontal (28.0%), 50 temporal (27.5%), 22 parietal (12.1%), and 7 occipital tumors (3.8%) identified. Multifocal disease was noted in 38 patients (20.9%). Tumors affecting temporal lobe were associated with reduced overall survival when compared to all other tumors (11.0 months vs. 13.0 months, log-rank p=0.0068). However, this disparity became insignificant when adjusted for tumor grade, age, and surgical approach [HR(95% CI) 1.26(0.87, 1.82), p=0.212]. Out of 82 cases tested for IDH-1, 10 were mutated (5.5%). IDH-1 mutation was present in 6 frontal, 2 temporal, 1 thalamic, and 1 multifocal tumor. Out of 21 cases tested for 1p19q deletions, 12 were co-deleted, 9 of which were frontal lobe tumors. MGMT methylation was assessed in 45 cases; 7 of 14 frontal tumors and 6 of 13 temporal tumors were methylated. ATRX loss was detected in 2/42 assessed cases.

Conclusions Results support the hypothesis that the anatomical locations influence patients’ clinical courses. Tumors involving the temporal lobe were associated with poorer survival, though this appeared to be driven by these more aggressive tumor biology and higher risk demographics. Molecular analysis was limited by low prevalence of genetic testing, highlighting the importance of capturing this information for all gliomas.

Authors/Disclosures
Christopher P. Mackintosh PRESENTER	No disclosure on file
Richard Butterfield	No disclosure on file
Nan Zhang	Nan Zhang has nothing to disclose.
	No disclosure on file
Bernard Bendok, MD (Mayo Clinic)	No disclosure on file
	No disclosure on file
	No disclosure on file
Alyx B. Porter, MD, FAAN (Mayo Clinic)	Dr. Porter has a non-compensated relationship as a Board Member with American Brain Foundation that is relevant to AAN interests or activities.
Maciej M. Mrugala, MD, PhD, MPH, FAAN (Mayo Clinic)	Dr. Mrugala has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Veevo Biomedicines Inc. Dr. Mrugala has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Arbor Pharmaceuticals. Dr. Mrugala has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Astra-Zeneca. Dr. Mrugala has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Servier. Dr. Mrugala has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Medscape. Dr. Mrugala has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Mrugala has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Kyiatec . The institution of Dr. Mrugala has received research support from Arbor Pharmaceuticals. Dr. Mrugala has a non-compensated relationship as a Program Director with Society for Neuro-Oncology that is relevant to AAN interests or activities.